search
Back to results

Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post TAVI (PACE-4-TAVI)

Primary Purpose

Atrioventricular Block, Second and Third Degree

Status
Not yet recruiting
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
conduction system pacing
right ventricular or biventricular pacing
Sponsored by
Medical University of Silesia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Atrioventricular Block, Second and Third Degree focused on measuring Pacemaker, Transcatheter Aortic Valve Replacement, Conduction System Pacing (CSP), Atrioventricular Block, Congestive Heart Failure, Bradycardia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: transcatheter aortic valve implantation (TAVI) in up to 30 days before qualification to pacemaker implantation Fulfilled criteria for permanent pacemaker implantation according do 2021 ESC guidelines Written informed consent Age of at least 18 years Exclusion Criteria: Permanent pacemaker implantation before TAVI procedure The occurrence of conduction disturbances more than 30 days after TAVI procedure No written informed consent Inability to obtain informed consent from participant Predicted inability to obtain cooperation from patient during observation period

Sites / Locations

  • Medical University of Silesia in Katowice

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Conduction System Pacing

Standard Pacing Method

Arm Description

Patients who receive Conduction System Pacing in form of Left Bundle Branch Area Pacing or His Bundle Pacing.

Patients who receive currently standard pacing method with exact type of ventricular pacing depending upon left ventricular ejection fraction (LVEF): right ventricular pacing in case of LVEF >= 40% or biventricular pacing if LVEF is determined to be less than 40%, as per current ESC guidelines.

Outcomes

Primary Outcome Measures

Heart Failure Hospitalization
Hospitalization due to heart failure as a main reason
All-cause death
Death from any cause

Secondary Outcome Measures

Change in exercise capacity
Improvement or deterioration in exercise capacity assessed as a change of ≥1 New York Heart Association (NYHA) functional class or a change in 6-Minute Walk Test (6MWT) distance by 55m or more
Response to Cardiac Resynchronization Therapy (CRT)
Meeting the echocardiographic criteria of response to CRT defined as a decrease in Left Ventricular End Systolic Volume by ≥15% or an increase in Left Ventricular Ejection Fraction by ≥5% from the baseline values
Pacing-Induced Cardiomyopathy (PICM)
Pacing-related CHF meeting the echocardiographic criteria of PICM defined as a decrease in LVEF by >=10% to the absolute value of <50%
Change in global longitudinal strain (GLS)
An increase in GLS value of 20 absolute percentage points from baseline or an increase above -16%.
Atrial Fibrillation (AF) episodes
Occurrence of the first episode of AF in a patient with no previous history of atrial fibrillation (AF).
Atrial High Rate Episodes (AHRE) in pacemaker recordings
Occurrence or change of the burden of AHRE events in the records from the CIED.
Change in the concentration of the N-terminal pro-brain natriuretic peptide (NT-proBNP)
pl/mL
Change in Quality of Life
Assessed with Short Form Health Survey (SF-36): 0 to 100; low QoL to high QoL - better outcome.

Full Information

First Posted
July 20, 2023
Last Updated
August 4, 2023
Sponsor
Medical University of Silesia
Collaborators
Medical Research Agency, Poland
search

1. Study Identification

Unique Protocol Identification Number
NCT05966675
Brief Title
Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post TAVI
Acronym
PACE-4-TAVI
Official Title
Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post Transcatheter Aortic Valve Implantation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
May 2028 (Anticipated)
Study Completion Date
June 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Silesia
Collaborators
Medical Research Agency, Poland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study aims to compare permanent Conduction System Pacing (CSP) with the standard therapy - Right Ventricular Pacing (RVP) or Biventricular Pacing (BVP) - in preventing the development and progression of symptomatic Chronic Heart Failure (CHF) and improving survival in patients after Transcatheter Aortic Valve Implantation (TAVI).
Detailed Description
A multicenter randomized controlled head-to-head trial was planned to compare the effects of permanent pacemaker implantation (PPMI) using CSP (study intervention) with currently standard therapy - RVP or BVP (control group). The study population will consist of patients hospitalized after TAVI complicated with high-degree persistent atrioventricular (AV) block or newly developed complex AV or intraventricular conduction disturbances, qualified for PPMI within 30 days after surgery, following the 2021 European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrioventricular Block, Second and Third Degree
Keywords
Pacemaker, Transcatheter Aortic Valve Replacement, Conduction System Pacing (CSP), Atrioventricular Block, Congestive Heart Failure, Bradycardia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients will be randomized 1:1 to the intervention and control groups. In the control group, the type of ventricular pacing will depend on the left ventricular ejection fraction (LVEF): 1) RVP is planned in the group of patients with LVEF ≥40%, 2) BVP is planned in the group of patients with LVEF <40%, following current ESC guidelines.
Masking
Participant
Masking Description
Patient will be blind to type of intervention. Due to a need of method-specific use of hardware and tailored programming of cardiac devices, medical staff is impossible to blind. The inability to blind affects also echocardiographists and anyone performing device interrogation as significant differences in number and localisation of pacing leads, their electrical parameters and pacemaker settings are inherently different in studied arms.
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conduction System Pacing
Arm Type
Experimental
Arm Description
Patients who receive Conduction System Pacing in form of Left Bundle Branch Area Pacing or His Bundle Pacing.
Arm Title
Standard Pacing Method
Arm Type
Active Comparator
Arm Description
Patients who receive currently standard pacing method with exact type of ventricular pacing depending upon left ventricular ejection fraction (LVEF): right ventricular pacing in case of LVEF >= 40% or biventricular pacing if LVEF is determined to be less than 40%, as per current ESC guidelines.
Intervention Type
Device
Intervention Name(s)
conduction system pacing
Intervention Description
Implantation of cardiac implantable electronic device (CIED) with conduction system pacing (left bundle branch area pacing or his bundle pacing).
Intervention Type
Device
Intervention Name(s)
right ventricular or biventricular pacing
Intervention Description
Implantation of cardiac implantable electronic device with right ventricular or biventricular pacing according to left ventricular ejection fraction and current ESC guidelines.
Primary Outcome Measure Information:
Title
Heart Failure Hospitalization
Description
Hospitalization due to heart failure as a main reason
Time Frame
12 months
Title
All-cause death
Description
Death from any cause
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in exercise capacity
Description
Improvement or deterioration in exercise capacity assessed as a change of ≥1 New York Heart Association (NYHA) functional class or a change in 6-Minute Walk Test (6MWT) distance by 55m or more
Time Frame
24 months
Title
Response to Cardiac Resynchronization Therapy (CRT)
Description
Meeting the echocardiographic criteria of response to CRT defined as a decrease in Left Ventricular End Systolic Volume by ≥15% or an increase in Left Ventricular Ejection Fraction by ≥5% from the baseline values
Time Frame
24 months
Title
Pacing-Induced Cardiomyopathy (PICM)
Description
Pacing-related CHF meeting the echocardiographic criteria of PICM defined as a decrease in LVEF by >=10% to the absolute value of <50%
Time Frame
24 months
Title
Change in global longitudinal strain (GLS)
Description
An increase in GLS value of 20 absolute percentage points from baseline or an increase above -16%.
Time Frame
24 months
Title
Atrial Fibrillation (AF) episodes
Description
Occurrence of the first episode of AF in a patient with no previous history of atrial fibrillation (AF).
Time Frame
24 months
Title
Atrial High Rate Episodes (AHRE) in pacemaker recordings
Description
Occurrence or change of the burden of AHRE events in the records from the CIED.
Time Frame
24 months
Title
Change in the concentration of the N-terminal pro-brain natriuretic peptide (NT-proBNP)
Description
pl/mL
Time Frame
24 months
Title
Change in Quality of Life
Description
Assessed with Short Form Health Survey (SF-36): 0 to 100; low QoL to high QoL - better outcome.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: transcatheter aortic valve implantation (TAVI) in up to 30 days before qualification to pacemaker implantation Fulfilled criteria for permanent pacemaker implantation according do 2021 ESC guidelines Written informed consent Age of at least 18 years Exclusion Criteria: Permanent pacemaker implantation before TAVI procedure The occurrence of conduction disturbances more than 30 days after TAVI procedure No written informed consent Inability to obtain informed consent from participant Predicted inability to obtain cooperation from patient during observation period
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Krzysztof S. Gołba, MD PhD
Phone
+48 (32)359-88-93
Email
krzysztof.golba@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tomasz Soral, MD
Email
tomasz.soral@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Krzysztof S. Gołba, MD PhD
Organizational Affiliation
Silesian Medical University in Katowice
Official's Role
Study Chair
Facility Information:
Facility Name
Medical University of Silesia in Katowice
City
Katowice
Country
Poland
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Krzysztof S. Gołba, MD PhD
Email
k.golba@sum.edu.pl
First Name & Middle Initial & Last Name & Degree
Tomasz Soral, MD
Email
tomasz.soral@gmail.com
First Name & Middle Initial & Last Name & Degree
Danuta Łoboda, MD, PhD
First Name & Middle Initial & Last Name & Degree
Rafał Gardas, MD, PhD
First Name & Middle Initial & Last Name & Degree
Jolanta Biernat, MD, PhD
First Name & Middle Initial & Last Name & Degree
Grzegorz Jarosiński, MD, PhD
First Name & Middle Initial & Last Name & Degree
Tomasz Soral, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
34455430
Citation
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabes JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo JC, Delgado V, Diller GP, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylen I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021 Sep 14;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364. No abstract available. Erratum In: Eur Heart J. 2022 May 1;43(17):1651.
Results Reference
background
PubMed Identifier
21798880
Citation
Shimony A, Eisenberg MJ, Filion KB, Amit G. Beneficial effects of right ventricular non-apical vs. apical pacing: a systematic review and meta-analysis of randomized-controlled trials. Europace. 2012 Jan;14(1):81-91. doi: 10.1093/europace/eur240. Epub 2011 Jul 27.
Results Reference
background
PubMed Identifier
9474680
Citation
Daubert JC, Ritter P, Le Breton H, Gras D, Leclercq C, Lazarus A, Mugica J, Mabo P, Cazeau S. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol. 1998 Jan;21(1 Pt 2):239-45. doi: 10.1111/j.1540-8159.1998.tb01096.x.
Results Reference
background
PubMed Identifier
27016475
Citation
Dandamudi G, Vijayaraman P. How to perform permanent His bundle pacing in routine clinical practice. Heart Rhythm. 2016 Jun;13(6):1362-6. doi: 10.1016/j.hrthm.2016.03.040. Epub 2016 Mar 22. No abstract available.
Results Reference
background
PubMed Identifier
31233818
Citation
Huang W, Chen X, Su L, Wu S, Xia X, Vijayaraman P. A beginner's guide to permanent left bundle branch pacing. Heart Rhythm. 2019 Dec;16(12):1791-1796. doi: 10.1016/j.hrthm.2019.06.016. Epub 2019 Jun 22. No abstract available.
Results Reference
background
PubMed Identifier
30707037
Citation
Jastrzebski M, Moskal P, Bednarek A, Kielbasa G, Vijayaraman P, Czarnecka D. Programmed His Bundle Pacing: A Novel Maneuver for the Diagnosis of His Bundle Capture. Circ Arrhythm Electrophysiol. 2019 Feb;12(2):e007052. doi: 10.1161/CIRCEP.118.007052.
Results Reference
background
PubMed Identifier
31930753
Citation
Jastrzebski M, Moskal P, Bednarek A, Kielbasa G, Kusiak A, Sondej T, Bednarski A, Vijayaraman P, Czarnecka D. Programmed deep septal stimulation: A novel maneuver for the diagnosis of left bundle branch capture during permanent pacing. J Cardiovasc Electrophysiol. 2020 Feb;31(2):485-493. doi: 10.1111/jce.14352. Epub 2020 Jan 20.
Results Reference
background
PubMed Identifier
25616819
Citation
Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, El-Chami MF, Herrmann HC, Mack M, Makkar RR, Miller DC, Pichard A, Tuzcu EM, Szeto WY, Webb JG, Moses JW, Smith CR, Williams MR, Leon MB, Kodali SK; PARTNER Publications Office. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):60-9. doi: 10.1016/j.jcin.2014.07.022.
Results Reference
background
PubMed Identifier
32030230
Citation
Xi Z, Liu T, Liang J, Zhou YJ, Liu W. Impact of postprocedural permanent pacemaker implantation on clinical outcomes after transcatheter aortic valve replacement: a systematic review and meta-analysis. J Thorac Dis. 2019 Dec;11(12):5130-5139. doi: 10.21037/jtd.2019.12.02.
Results Reference
background
PubMed Identifier
35837611
Citation
Xu S, Zhang E, Qian Z, Sun J, Zou F, Wang Y, Hou X, Zou J. Mid- to Long-Term Clinical and Echocardiographic Effects of Post-procedural Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022 Jun 28;9:911234. doi: 10.3389/fcvm.2022.911234. eCollection 2022.
Results Reference
background
PubMed Identifier
27832844
Citation
Fadahunsi OO, Olowoyeye A, Ukaigwe A, Li Z, Vora AN, Vemulapalli S, Elgin E, Donato A. Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis From the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016 Nov 14;9(21):2189-2199. doi: 10.1016/j.jcin.2016.07.026.
Results Reference
background

Learn more about this trial

Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post TAVI

We'll reach out to this number within 24 hrs